371725
GPR43 Agonist
>98% (HPLC), solid
Synonyme(s) :
GPR43 (FFA2) Agonist, (S)-2-(4-chlorophenyl)-3,3-dimethyl-N-(5-phenylthiazol-2-yl)butanamide
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C21H21ClN2OS
Numéro CAS:
Poids moléculaire :
384.92
MDL number:
UNSPSC Code:
51111800
NACRES:
NA.77
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
GPR43 (FFA2) Agonist, The GPR43 (FFA2) Agonist controls the biological activity of GPR43. This small molecule/inhibitor is primarily used for Biochemicals applications.
Quality Level
assay
>98% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white
solubility
DMSO: 50 mg/mL
shipped in
ambient
storage temp.
2-8°C
General description
A phenylacetamide compound that acts as an allosteric agonist of FFA2 (GPR43), demonstrating a left-shifted acetate dose response (IC50 = 0.7 µM) and 111% efficacy relative to acetate in hFFA2 forskolin-induced cAMP assays.
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Wang, Y., et al. 2009. Bioorg. Med. Chem. Lett.20, 493.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificats d'analyse (COA)
Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Sandra M Holmberg et al.
Nature communications, 15(1), 3502-3502 (2024-04-26)
Beneficial gut bacteria are indispensable for developing colonic mucus and fully establishing its protective function against intestinal microorganisms. Low-fiber diet consumption alters the gut bacterial configuration and disturbs this microbe-mucus interaction, but the specific bacteria and microbial metabolites responsible for
Anne Ørgaard et al.
Islets, 11(5), 103-111 (2019-08-31)
The intestinal microbiota has been demonstrated to influence host metabolism, and has been proposed to affect the development of obesity and type 2 diabetes (T2D), possibly through short-chain fatty acids (SCFAs) produced by fermentation of dietary fiber. There are some
Signe Schultz Pedersen et al.
The FEBS journal, 291(3), 566-583 (2023-11-21)
Butyrate, a gut microbial metabolite, has beneficial effects on glucose homeostasis and has become an attractive drug candidate for type 2 diabetes (T2D). Recently, we showed that butyrate protects pancreatic beta cells against cytokine-induced dysfunction. In this study, we explored